Creating master cell banks for new SARS-CoV-2 vaccines
Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines
This study is working on creating special cell banks to help make better vaccines for COVID-19, which could lead to more effective options for patients in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project ID | NIH-11202800 on NIH RePORTER |
What this research studies
This research focuses on the manufacturing and characterization of master cell banks that are essential for developing next-generation vaccines against SARS-CoV-2. It involves a comprehensive approach that includes product development planning, optimization, and compliant manufacturing processes for clinical studies. Patients may benefit from the advancements in vaccine technology that this research aims to achieve, potentially leading to more effective vaccines against COVID-19. The project also includes regulatory support to ensure that new vaccines meet safety and efficacy standards.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals who are at risk of COVID-19 or those involved in clinical trials for new vaccines.
Not a fit: Patients who are not at risk for COVID-19 or those who have already been vaccinated with existing vaccines may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against COVID-19, improving public health outcomes.
How similar studies have performed: Other research has shown success in developing vaccines using similar manufacturing and characterization approaches, indicating a promising path forward.
Where this research is happening
Dessau-Rosslau, Germany
- Idt Biologika Gmbh — Dessau-Rosslau, Germany (Active)
Researchers
- Principal investigator: Trusheim, Heidi — Idt Biologika Gmbh
- Study coordinator: Trusheim, Heidi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.